Literature DB >> 15653263

N-acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration.

Vicente Molina1, Javier Sánchez, Santiago Reig, Javier Sanz, Carlos Benito, Cristina Santamarta, Javier Pascau, Fernando Sarramea, Juan D Gispert, José M Misiego, Tomás Palomo, Manuel Desco.   

Abstract

Magnetic resonance spectroscopy studies in schizophrenia have revealed consistently reduced N-acetyl aspartate (NAA) levels in chronic patients, but not in recent-onset patients. Studies on the relationship between this marker and disease duration have commonly been negative, although it is also true that they have been conducted in patients with long-standing disease. We compared NAA levels in the dorsolateral prefrontal cortex in 16 recent-onset patients (duration: 1.8+/-0.6 years), 19 chronic patients (duration: 9.7+/-6.1 years), and 20 healthy controls. We studied the NAA/creatine and choline/creatine ratios in the dorsolateral prefrontal cortex in both hemispheres, controlling for the effect of age. Chronic patients had significantly lower NAA/Cr ratios in the left hemisphere compared to recent-onset patients and healthy controls, with no difference in Cho/Cr ratio. There were no differences between controls and recent-onset patients. There was a significant inverse relationship between left-side NAA/Cr and disease duration, suggesting that prefrontal NAA levels may progressively decrease in schizophrenia. Taken within the context of the existing literature, these results indicate that this process may be limited to the early years following the onset of the disease. Therefore, reduced prefrontal levels of NAA may be limited to chronic schizophrenia patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15653263     DOI: 10.1016/j.schres.2004.02.001

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  15 in total

1.  Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia.

Authors:  Melissa Terpstra; T J Vaughan; Kamil Ugurbil; Kelvin O Lim; S Charles Schulz; Rolf Gruetter
Journal:  MAGMA       Date:  2005-11-18       Impact factor: 2.310

Review 2.  Methodological issues in current antipsychotic drug trials.

Authors:  Stefan Leucht; Stephan Heres; Johannes Hamann; John M Kane
Journal:  Schizophr Bull       Date:  2008-01-29       Impact factor: 9.306

Review 3.  Neurochemistry of drug action: insights from proton magnetic resonance spectroscopic imaging and their relevance to addiction.

Authors:  Stephanie C Licata; Perry F Renshaw
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

Review 4.  Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis.

Authors:  Nina Vanessa Kraguljac; Meredith Reid; David White; Rebecca Jones; Jan den Hollander; Deborah Lowman; Adrienne Carol Lahti
Journal:  Psychiatry Res       Date:  2012-09-13       Impact factor: 3.222

5.  Proton magnetic resonance spectroscopy and thought disorder in childhood schizophrenia.

Authors:  Ronald R Seese; Joseph O'Neill; Matthew Hudkins; Prabha Siddarth; Jennifer Levitt; Ben Tseng; Keng Nei Wu; Rochelle Caplan
Journal:  Schizophr Res       Date:  2011-08-27       Impact factor: 4.939

6.  Reduced N-acetyl-aspartate levels in schizophrenia patients with a younger onset age: a single-voxel 1H spectroscopy study.

Authors:  Jeffrey A Stanley; Madhuri Vemulapalli; Jeffrey Nutche; Debra M Montrose; John A Sweeney; Jay W Pettegrew; Frank P MacMaster; Matcheri S Keshavan
Journal:  Schizophr Res       Date:  2007-05-10       Impact factor: 4.939

Review 7.  T2 relaxation effects on apparent N-acetylaspartate concentration in proton magnetic resonance studies of schizophrenia.

Authors:  Bethany K Bracken; Elizabeth D Rouse; Perry F Renshaw; David P Olson
Journal:  Psychiatry Res       Date:  2013-06-12       Impact factor: 3.222

Review 8.  α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future.

Authors:  Alvin V Terry; Patrick M Callahan
Journal:  Neuropharmacology       Date:  2020-03-15       Impact factor: 5.250

9.  N-Acetyl-Aspartate Level is Decreased in the Prefrontal Cortex in Subjects At-Risk for Schizophrenia.

Authors:  Marine Mondino; Jerome Brunelin; Mohamed Saoud
Journal:  Front Psychiatry       Date:  2013-09-05       Impact factor: 4.157

10.  A Review of Magnetic Resonance Spectroscopy Studies in Marijuana using Adolescents and Adults.

Authors:  Jennifer T Sneider; Yasmin Mashhoon; Marisa M Silveri
Journal:  J Addict Res Ther       Date:  2013-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.